| Business Summary | | Keryx
Biopharmaceuticals
uses
data
discovered
through
the
mapping
of
the
human
genome
to
generate
drug
candidates
that
target
the
regulation
of
protein
kinases.
Protein
kinases
play
a
key
role
in
the
way
cells
communicate.
The
Company's
KinAce
platform
has
produced
13
lead
compounds,
eight
of
which
have
already
produced
positive
results
in
animal
(in
vivo)
tests.
In
addition
to
developing
drug
candidates
with
its
KinAce
platform,
the
Company
has
an
exclusive
license
to
sulodexide
(KRX-101)
in
North
America,
Japan
and
other
important
markets,
and
is
developing
it
for
the
treatment
of
a
kidney
disease
known
as
diabetic
nephropathy.
To
date,
none
of
Keryx's
drug
candidates
has
received
approval
for
sale
in
any
market. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Keryx
Biophamaceutical,
Inc.
is
a
developemental
stage
company
formed
to
use
data
discovered
through
the
mapping
of
the
human
genome
to
generate
drug
candidates.
For
the
six
months
ended
6/30/01,
the
Company
reports
no
revenues
for
both
fiscal
periods.
Net
loss
increased
2%
to
$5.8
million.
Results
reflect
the
absence
of
any
revenue-generating
activities,
and
expenses
related
to
the
hiring
of
additional
R&D
personnel
and
pre-clinical
work. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Morris Laster, M.D., 36 Chairman,
CEO | $366K | Benjamin Corn, M.D., 40 Pres | 216K | Robert Gallahue, Jr., 40 CFO,
Treasurer | -- | Ira Weinstein, 45 COO | 137K | Noa Shelach VP | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|